ARTICLE | Company News
Mundipharma gains rights to develop and commercialize Grafalon in China and Japan
July 20, 2018 5:24 PM UTC
Neovii Pharmaceuticals AG (Rapperswil, Switzerland) granted Mundipharma International Ltd. (Dublin, Ireland) rights to develop and promote Grafalon in China and Japan starting at the end of October. Grafalon is approved in China to prevent and treat acute steroid resistant rejection in solid organ transplant. ...